Phibro Animal Health (PAHC) Competitors $29.18 -0.26 (-0.88%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$29.41 +0.23 (+0.80%) As of 07/25/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PAHC vs. PCVX, MTSR, CYTK, MRUS, KRYS, AKRO, RNA, ADMA, SRRK, and ACADShould you be buying Phibro Animal Health stock or one of its competitors? The main competitors of Phibro Animal Health include Vaxcyte (PCVX), Metsera (MTSR), Cytokinetics (CYTK), Merus (MRUS), Krystal Biotech (KRYS), Akero Therapeutics (AKRO), Avidity Biosciences (RNA), ADMA Biologics (ADMA), Scholar Rock (SRRK), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Phibro Animal Health vs. Its Competitors Vaxcyte Metsera Cytokinetics Merus Krystal Biotech Akero Therapeutics Avidity Biosciences ADMA Biologics Scholar Rock ACADIA Pharmaceuticals Vaxcyte (NASDAQ:PCVX) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment. Do analysts prefer PCVX or PAHC? Vaxcyte currently has a consensus price target of $136.50, suggesting a potential upside of 272.65%. Phibro Animal Health has a consensus price target of $24.40, suggesting a potential downside of 16.38%. Given Vaxcyte's stronger consensus rating and higher possible upside, research analysts plainly believe Vaxcyte is more favorable than Phibro Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Phibro Animal Health 2 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.83 Which has higher earnings & valuation, PCVX or PAHC? Phibro Animal Health has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$463.93M-$3.99-9.18Phibro Animal Health$1.02B1.16$2.42M$0.7837.41 Is PCVX or PAHC more profitable? Phibro Animal Health has a net margin of 2.68% compared to Vaxcyte's net margin of 0.00%. Phibro Animal Health's return on equity of 30.51% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -17.12% -16.26% Phibro Animal Health 2.68%30.51%6.89% Do institutionals & insiders have more ownership in PCVX or PAHC? 96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, PCVX or PAHC? Vaxcyte has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Does the media refer more to PCVX or PAHC? In the previous week, Vaxcyte had 5 more articles in the media than Phibro Animal Health. MarketBeat recorded 6 mentions for Vaxcyte and 1 mentions for Phibro Animal Health. Vaxcyte's average media sentiment score of 1.66 beat Phibro Animal Health's score of 1.30 indicating that Vaxcyte is being referred to more favorably in the media. Company Overall Sentiment Vaxcyte Very Positive Phibro Animal Health Positive SummaryPhibro Animal Health beats Vaxcyte on 9 of the 16 factors compared between the two stocks. Get Phibro Animal Health News Delivered to You Automatically Sign up to receive the latest news and ratings for PAHC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PAHC vs. The Competition Export to ExcelMetricPhibro Animal HealthMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$10.55B$5.70B$9.50BDividend Yield1.63%2.00%4.58%4.00%P/E Ratio37.4117.3728.3920.08Price / Sales1.1629.18430.0899.95Price / Cash13.9323.0336.2258.56Price / Book4.603.698.675.88Net Income$2.42M$234.77M$3.25B$258.89M7 Day Performance-0.78%6.32%4.30%3.70%1 Month Performance16.16%7.94%10.57%11.71%1 Year Performance54.56%-13.57%35.68%17.98% Phibro Animal Health Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PAHCPhibro Animal Health4.0897 of 5 stars$29.18-0.9%$24.40-16.4%+55.0%$1.19B$1.02B37.411,940Positive NewsPCVXVaxcyte1.7946 of 5 stars$35.64-1.6%$136.50+283.0%-56.2%$4.67BN/A-8.93160News CoveragePositive NewsMTSRMetseraN/A$39.91-6.6%$55.00+37.8%N/A$4.49BN/A0.0081Lockup ExpirationGap UpCYTKCytokinetics4.145 of 5 stars$36.96-0.7%$70.92+91.9%-36.4%$4.45B$18.47M-6.99250News CoverageMRUSMerus1.8941 of 5 stars$62.37-1.4%$84.64+35.7%+23.0%$4.38B$54.73M-15.2937Upcoming EarningsKRYSKrystal Biotech4.8912 of 5 stars$148.09+0.4%$213.75+44.3%-29.9%$4.26B$290.52M35.60210News CoverageAnalyst ForecastAKROAkero Therapeutics3.8068 of 5 stars$51.38-1.3%$82.50+60.6%+78.5%$4.15BN/A-26.3530Positive NewsRNAAvidity Biosciences2.1351 of 5 stars$34.02+0.8%$66.35+95.0%-18.9%$4.07B$10.90M-11.34190News CoverageADMAADMA Biologics3.6012 of 5 stars$17.13+2.4%$27.67+61.5%+37.7%$3.99B$426.45M20.15530News CoverageSRRKScholar Rock3.43 of 5 stars$41.12+1.0%$42.67+3.8%+312.2%$3.87B$33.19M-16.25140Positive NewsACADACADIA Pharmaceuticals4.1503 of 5 stars$22.28-1.2%$27.88+25.1%+25.3%$3.78B$996.28M16.26510Positive NewsAnalyst Forecast Related Companies and Tools Related Companies PCVX Competitors MTSR Competitors CYTK Competitors MRUS Competitors KRYS Competitors AKRO Competitors RNA Competitors ADMA Competitors SRRK Competitors ACAD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PAHC) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phibro Animal Health Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Phibro Animal Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
